This Small Biotech Stock Is Surging Today. Here's Why. [Yahoo! Finance]
Tourmaline Bio, Inc. (TRML)
Company Research
Source: Yahoo! Finance
KEY TAKEAWAYS Novartis said Tuesday it is buying Tourmaline Bio for $1.4 billion, in a deal that gives the Swiss pharma giant access to the biotech's late-stage cardiovascular drug pacibekitug. Novartis said it would offer Tourmaline Bio shareholders $48 a share, an almost 60% premium to Tourmaline's closing price Monday of $30.18. Wedbush downgraded its rating for Tourmaline to "neutral" at the $48 price, noting that Novartis will be able to help Tourmaline advance progress in pacibekitug. Tourmaline Bio ( TRML ) shares have had a strong run this year. News that Swiss pharma giant Novartis ( NVS ) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost. On Tuesday, Novartis said it is buying Tourmaline for $48 per share, an almost 60% premium to Tourmaline's closing price Monday of $30.18. The deal, expected to close in the fourth quarter, gives Novartis access to Tourmaline's targeted therapy drug paci
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio (NASDAQ:TRML) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- $HAREHOLDER ALERT: The M&A Class Action Continues to Investigate Merger – TRML, PNFP, MRCC, and UNPGlobeNewswire
- Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLBusiness Wire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AL, TRML, SOL on Behalf of ShareholdersPR Newswire
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)PR Newswire
TRML
Earnings
- 8/13/25 - Beat
TRML
Sec Filings
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- TRML's page on the SEC website